FENNEC PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-09-30 was 92.00K shares, a 39.07% decline year-over-year.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-06-30 was 95.00K shares, a 400.00% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-03-31 was 49.00K shares, a 88.46% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2022-09-30 was 151.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2023-09-30 | 92.00K shares 10-Q · filed 2023-11-09 | |
| 2023-06-30 | 95.00K shares 10-Q · filed 2023-11-09 | |
| 2023-03-31 | 49.00K shares 10-Q · filed 2023-11-09 | |
| 2022-09-30 | 151.00K shares 10-Q · filed 2022-11-14 | |
| 2022-06-30 | 19.00K shares 10-Q · filed 2022-11-14 | |
| 2022-03-31 | 26.00K shares 10-Q · filed 2022-11-14 | |
| 2016-09-30 | 324.00K shares 10-Q · filed 2017-11-13 | |
| 2016-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-12 | |
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |